Skip to content

PolitiKit

Lobbying by Emergent BioSolutions Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Client of a consultant lobbyist

Emergent BioSolutions Canada Inc.

Meetings this Parliament
45
With MPs
9
Since Nov 2021
45
Active registrations
1

Most recent reported meeting: Oct 23, 2026.

Registrations in effect

Consultant In effect since Oct 6, 2026

Consultant Kait LaForce of Counsel Public Affairs Inc.

Consultant lobbyists

  • Kait LaForce Former public office holder

    Formerly Manager, Office of Member of Parliament Filomena Tassi, House of Commons (2017–2018)

    Formerly Writer, Liberal Research Bureau, House of Commons (2016–2017)

  • Kait LaForce Former public office holder

    Formerly Manager, Office of Member of Parliament Filomena Tassi, House of Commons (2017–2018)

    Formerly Writer, Liberal Research Bureau, House of Commons (2016–2017)

  • Kait LaForce Former public office holder

    Formerly Manager, Office of Member of Parliament Filomena Tassi, House of Commons (2017–2018)

    Formerly Writer, Liberal Research Bureau, House of Commons (2016–2017)

Institutions they may lobby: Canada Revenue Agency (CRA), Correctional Service of Canada (CSC), Crown-Indigenous Relations and Northern Affairs Canada (CIRNAC), Finance Canada (FIN), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), National Defence (DND), Prairies Economic Development Canada (PrairiesCan), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Safety Canada (PS), Royal Canadian Mounted Police (RCMP), Senate of Canada, Veterans Affairs Canada (VAC)

What they're lobbying on (8)
  • Engagement as part of the federal pre-budget consultation process regarding supply chain priorities, challenges and recommendation for consideration in the 2026 budget
  • Engage government regarding the need for sustainable manufacturing, procurement and stockpiling of medical countermeasures used to diagnose, prevent, or treat diseases related to chemical, biological, radiological, or nuclear threats.
  • Engage National Defence, Health, and Global Affairs Canada on national readiness in response to emerging global health threats.
  • To work with government to make NARCAN® (Naloxone HCI) Nasal Spray more widely available across Canada to facilitate immediate treatment to individuals suffering from opioid overdose.
  • Eligibility for Scientific Research and Experimental Development tax incentives.
  • Discuss changes to take home naloxone program.
  • Engage Health and National Defence concerning Emergent's Winnipeg facility for the production of medical countermeasures.
  • Seek funding support from the Strategic Innovation Fund to expand Emergent's Winnipeg facility.

Registration 940796-382308-5. Look it up in the official Registry

Reported meetings

Spreadsheet
  • Reported by Kait LaForce · Consultant

    • Tim Smith · Deputy Program Manager, National Defence (DND)
    • Natasha Singh · Director, National Defence (DND)
    • Jocelyn Milburn · Director, Innovation, Science and Economic Development Canada (ISED)
    • Amanda Jane · Strategic Planner, Innovation, Science and Economic Development Canada (ISED)
    Engage National Defence, Health, and Global Affairs Canada on national readiness in response to emerging global health threats. Read more

    Engage government regarding the need for sustainable manufacturing, procurement and stockpiling of medical countermeasures used to diagnose, prevent, or treat diseases related to chemical, biological, radiological, or nuclear threats.

    Official report

  • Reported by Kait LaForce · Consultant

    • Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
    Engage government regarding the need for sustainable manufacturing, procurement and stockpiling of medical countermeasures used to diagnose, prevent, or treat diseases related to chemical, biological, radiological, or nuclear threats. Read more

    Engage National Defence, Health, and Global Affairs Canada on national readiness in response to emerging global health threats.

    Official report

  • Reported by Kait LaForce · Consultant

    • Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
    Engage government regarding the need for sustainable manufacturing, procurement and stockpiling of medical countermeasures used to diagnose, prevent, or treat diseases related to chemical, biological, radiological, or nuclear threats. Read more

    Engage National Defence, Health, and Global Affairs Canada on national readiness in response to emerging global health threats.

    Official report

  • Reported by Kait LaForce · Consultant

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
    Engage Health and National Defence concerning Emergent's Winnipeg facility for the production of medical countermeasures. Read more

    Engage National Defence, Health, and Global Affairs Canada on national readiness in response to emerging global health threats.

    Official report

  • Reported by Kait LaForce · Consultant

    • Chris Minaker · Director of Policy, Prairies Economic Development Canada (PrairiesCan)
    • Nathalie Leroux · Director General, Prairies Economic Development Canada (PrairiesCan)
    • Benoit Leduc · Manager, Innovation, Science and Economic Development Canada (ISED)
    • Nadeen Abd El Aal · Senior Policy Analyst, Innovation, Science and Economic Development Canada (ISED)
    and 2 more
    • Razan Shahin · Sector Analyst, Innovation, Science and Economic Development Canada (ISED)
    • Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
    Engage Health and National Defence concerning Emergent's Winnipeg facility for the production of medical countermeasures. Read more

    Engage National Defence, Health, and Global Affairs Canada on national readiness in response to emerging global health threats.

    Official report

  • Reported by Kait LaForce · Consultant

    • Tim Smith · Deputy Program Manager, National Defence (DND)
    • Wendy Hepburn · Deputy Director, National Defence (DND)
    • Chris Minaker · Director of Policy, Prairies Economic Development Canada (PrairiesCan)
    • Paul Eagan · Medical Consultant, National Defence (DND)
    Engage Health and National Defence concerning Emergent's Winnipeg facility for the production of medical countermeasures. Read more

    Engage National Defence, Health, and Global Affairs Canada on national readiness in response to emerging global health threats.

    Official report

  • Reported by Kait LaForce · Consultant

    • Bryn Savage · Senior policy advisor, Health Canada (HC)
    To work with government to make NARCAN® (Naloxone HCI) Nasal Spray more widely available across Canada to facilitate immediate treatment to individuals suffering from opioid overdose. Read more

    Official report

  • Reported by Kait LaForce · Consultant

    • Bryn Savage · Senior policy advisor, Innovation, Science and Economic Development Canada (ISED)
    To work with government to make NARCAN® (Naloxone HCI) Nasal Spray more widely available across Canada to facilitate immediate treatment to individuals suffering from opioid overdose. Read more

    Official report

  • Reported by Kait LaForce · Consultant

    Engage government regarding the need for sustainable manufacturing, procurement and stockpiling of medical countermeasures used to diagnose, prevent, or treat diseases related to chemical, biological, radiological, or nuclear threats. Read more

    Official report

  • Reported by Kait LaForce · Consultant

    • Jennifer Novak · Director General, Indigenous Services Canada (ISC)
    To work with government to make NARCAN® (Naloxone HCI) Nasal Spray more widely available across Canada to facilitate immediate treatment to individuals suffering from opioid overdose. Read more

    Official report

  • Reported by Kait LaForce · Consultant

    • Manuela Tomic · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Engage government regarding the need for sustainable manufacturing, procurement and stockpiling of medical countermeasures used to diagnose, prevent, or treat diseases related to chemical, biological, radiological, or nuclear threats. Read more

    Official report

  • Reported by Kait LaForce · Consultant

    • Manuela Tomic · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Engage government regarding the need for sustainable manufacturing, procurement and stockpiling of medical countermeasures used to diagnose, prevent, or treat diseases related to chemical, biological, radiological, or nuclear threats. Read more

    Official report

  • Reported by Kait LaForce · Consultant

    • Ian Cameron · Director of Strategy, Innovation, Science and Economic Development Canada (ISED)
    Engage government regarding the need for sustainable manufacturing, procurement and stockpiling of medical countermeasures used to diagnose, prevent, or treat diseases related to chemical, biological, radiological, or nuclear threats. Read more

    Official report

  • Reported by Kait LaForce · Consultant

    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Engage Health and National Defence concerning Emergent's Winnipeg facility for the production of medical countermeasures.

    Official report

  • Reported by Kait LaForce · Consultant

    • Jennifer Novak · Director General, Indigenous Services Canada (ISC)
    Discuss changes to take home naloxone program. Read more

    To work with government to make NARCAN® (Naloxone HCI) Nasal Spray more widely available across Canada to facilitate immediate treatment to individuals suffering from opioid overdose.

    Official report

  • Reported by Kait LaForce · Consultant

    • Jibril Hussein · Senior Policy Advisor, Health Canada (HC)
    To work with government to make NARCAN® (Naloxone HCI) Nasal Spray more widely available across Canada to facilitate immediate treatment to individuals suffering from opioid overdose. Read more

    Official report

  • Reported by Kait LaForce · Consultant

    • Manuela Tomic · Senior Policy Advsior, Innovation, Science and Economic Development Canada (ISED)
    Engage Health and National Defence concerning Emergent's Winnipeg facility for the production of medical countermeasures.

    Official report

  • Reported by Kait LaForce · Consultant

    • Jibril Hussein · Senior Policy Advisor, Health Canada (HC)
    To work with government to make NARCAN® (Naloxone HCI) Nasal Spray more widely available across Canada to facilitate immediate treatment to individuals suffering from opioid overdose. Read more

    Official report

  • Reported by Kait LaForce · Consultant

    To work with government to make NARCAN® (Naloxone HCI) Nasal Spray more widely available across Canada to facilitate immediate treatment to individuals suffering from opioid overdose. Read more

    Official report

  • Reported by Kait LaForce · Consultant

    To work with government to make NARCAN® (Naloxone HCI) Nasal Spray more widely available across Canada to facilitate immediate treatment to individuals suffering from opioid overdose. Read more

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.